BIOLOGIC/DISEASE-MODIFYING ANTIRHEUMATIC DRUG (DMARD)
Enbrel is a prescription medication approved by the Food and Drug Administration (FDA) to treat psoriatic arthritis, active ankylosing spondylitis, and moderate to severe plaque psoriasis, rheumatoid arthritis, and polyarticular juvenile idiopathic arthritis (JIA). Enbrel is also known by its drug name, Etanercept.
Enbrel is an immunomodulator, or in other words, a drug that modulates the immune system. It is considered a biologic disease-modifying antirheumatic drug (DMARD). Enbrel is a genetically engineered protein. Enbrel is believed to work by inhibiting tumor necrosis factor alpha (TNF-α), a chemical messenger involved in autoimmune attacks.
How do I take it?
Enbrel is administered once or twice weekly by subcutaneous injection.
Enbrel is available as a prefilled syringe, autoinjector, or multi-use vial.
The FDA-approved label for Enbrel lists common side effects including infections and injection site reactions.
Rare but serious side effects listed for Enbrel include congestive heart failure, lupus-like syndrome, demyelinating disease such as multiple sclerosis, blood cell disorders, severe allergic reactions or infections, and increased risk for developing certain types of cancer such as lymphoma.
For answers to frequently asked questions about exposure to Enbrel during pregnancy and breastfeeding, visit the experts at MothertoBaby.org.
For more details about this treatment, visit:
Enbrel – Amgen